Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Ontology highlight
SUBMITTER: Humby F
PROVIDER: S-EPMC7829614 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA